Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial

Detalles Bibliográficos
Autores principales: Schmidinger, M., Shariat, S.F., Fajkovic, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808104/
https://www.ncbi.nlm.nih.gov/pubmed/33421736
http://dx.doi.org/10.1016/j.esmoop.2020.100035
_version_ 1783636843839881216
author Schmidinger, M.
Shariat, S.F.
Fajkovic, H.
author_facet Schmidinger, M.
Shariat, S.F.
Fajkovic, H.
author_sort Schmidinger, M.
collection PubMed
description
format Online
Article
Text
id pubmed-7808104
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78081042021-01-22 Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial Schmidinger, M. Shariat, S.F. Fajkovic, H. ESMO Open Editorial Elsevier 2021-01-07 /pmc/articles/PMC7808104/ /pubmed/33421736 http://dx.doi.org/10.1016/j.esmoop.2020.100035 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Editorial
Schmidinger, M.
Shariat, S.F.
Fajkovic, H.
Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
title Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
title_full Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
title_fullStr Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
title_full_unstemmed Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
title_short Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
title_sort dual immune checkpoint inhibition in metastatic renal cell carcinoma: editorial re.: nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced rcc: extended 4-year follow-up of the phase iii checkmate 214 trial
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808104/
https://www.ncbi.nlm.nih.gov/pubmed/33421736
http://dx.doi.org/10.1016/j.esmoop.2020.100035
work_keys_str_mv AT schmidingerm dualimmunecheckpointinhibitioninmetastaticrenalcellcarcinomaeditorialrenivolumabplusipilimumabversussunitinibforfirstlinetreatmentofadvancedrccextended4yearfollowupofthephaseiiicheckmate214trial
AT shariatsf dualimmunecheckpointinhibitioninmetastaticrenalcellcarcinomaeditorialrenivolumabplusipilimumabversussunitinibforfirstlinetreatmentofadvancedrccextended4yearfollowupofthephaseiiicheckmate214trial
AT fajkovich dualimmunecheckpointinhibitioninmetastaticrenalcellcarcinomaeditorialrenivolumabplusipilimumabversussunitinibforfirstlinetreatmentofadvancedrccextended4yearfollowupofthephaseiiicheckmate214trial

Ejemplares similares